Karolinska Development AB (KDEV) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.58 M

Shareholding (Dec 2014)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength with a -148.31% CAGR growth in Operating Profits

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Finance

Market cap

SEK 227 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-999,999.00

Return on Equity

-0.70%

Price to Book

0.20

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Jun 2025)

Net Profit:

-73 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-63.01%

6 Months

-64.9%

1 Year

-67.18%

2 Years

-80.87%

3 Years

-81.89%

4 Years

-94.19%

5 Years

-84.43%

Karolinska Development AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-42.50%

EBIT Growth (5y)

-148.31%

EBIT to Interest (avg)

-16.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

10.32%

ROE (avg)

8.16%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.20

EV to EBIT

-17.92

EV to EBITDA

-20.11

EV to Capital Employed

0.15

EV to Sales

28.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.85%

ROE (Latest)

-0.70%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2014

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -34.04% vs -59.13% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -416.20% vs -176.34% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.10",
          "val2": "4.70",
          "chgp": "-34.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-73.10",
          "val2": "-14.00",
          "chgp": "-422.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.30",
          "val2": "-14.20",
          "chgp": "-416.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-23,857.60%",
          "val2": "-3,048.00%",
          "chgp": "-2,080.96%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 107.14% vs -9.68% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -250.00% vs 106.13% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.80",
          "val2": "2.80",
          "chgp": "107.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.20",
          "val2": "-1.10",
          "chgp": "-645.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.10",
          "val2": "5.40",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,580.30%",
          "val2": "-680.80%",
          "chgp": "-89.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.10

4.70

-34.04%

Operating Profit (PBDIT) excl Other Income

-73.10

-14.00

-422.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-73.30

-14.20

-416.20%

Operating Profit Margin (Excl OI)

-23,857.60%

-3,048.00%

-2,080.96%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -34.04% vs -59.13% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -416.20% vs -176.34% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5.80

2.80

107.14%

Operating Profit (PBDIT) excl Other Income

-8.20

-1.10

-645.45%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.10

5.40

-250.00%

Operating Profit Margin (Excl OI)

-1,580.30%

-680.80%

-89.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 107.14% vs -9.68% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -250.00% vs 106.13% in Dec 2023

All Annual Results

Company CV

About Karolinska Development AB

Karolinska Development AB

Finance

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Company Coordinates

Company Details

Tomtebodavagen 23 A , SOLNA None : 171 65

Tel: 46 8 52486070

http://www.karolinskadevelopment.com/

Registrar Details